Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Fluoxymesterone”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed1977

Fluoxymesterone therapy in anemia of patients on maintenance hemodialysis: comparison between patients with kidneys and anephric patients.

Nineteen patients with their kidneys and 11 anephric patients who were stable on maintenance hemodialysis received 20 mg a day of Fluoxymesterone. At the end of four months, there was a significant increase (p less than 0.005) in the mean hematocrit with a parallel increase in the hemoglobin level in both groups of patients. Concomitantly, we observed an increment of the red cell mass that was significant at the level of p less than 0.05. Blood transfusion requirements decreased significantly (p less than 0.1), independent of the presence or absence of kidneys. No changes in body weight, serum albumin, and serum cholesterol levels were observed. Secondary effects were hirsutism and hoarsening of the voice.

Adult↗
PubMedDate not supplied

Response to tamoxifen and fluoxymesterone in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen.

The response to tamoxifen or a combination of tamoxifen and fluoxymesterone was assessed in 54 postmenopausal breast cancer patients with recurrent disease. The patients had originally been entered in a randomized trial of 2 years of tamoxifen (40 mg daily), as an adjunct to primary surgery, versus no adjuvant endocrine therapy. The objective response rate (complete + partial) to the mentioned salvage endocrine therapies was significantly lower among patients from the tamoxifen group as compared to the controls (14% vs 54%; P less than 0.01). Their median time to disease progression was also significantly shorter (4 vs 15 months; P less than 0.05). Differences between the groups in regard to prognostic factors could not explain these differences. The lower response rate to these endocrine treatments was possibly one reason for the poorer survival outlook after relapse observed among the patients previously treated with adjuvant tamoxifen. An increased relapse-free survival achieved with adjuvant therapy may thus to some extent be offset by a poorer survival after relapse.

Aged↗
PubMed1984

Influence of fluoxymesterone on in vitro erythropoiesis affected by leukemic cells.

To investigate the influence of nonlymphocytic leukemic cells on normal erythropoietic burst-forming units (BFU-E), we cocultured leukemic cells at concentrations ranging from 0.5 to 5.0 X 10(5)/ml with 2 X 10(5) blood mononuclear cells or marrow nucleated cells from normal subjects in a BFU-E assay. The inhibitory effect of leukemic cells on burst formation by normal BFU-E was detected only at a high concentration (5 X 10(5)/ml). Leukemic-cell-conditioned medium (LCCM) was prepared by adding 1.25-10 X 10(6)/ml leukemic cells to culture medium. LCCM caused a dose-dependent inhibition of burst formation by normal BFU-E, but the medium prepared from normal cells did not. To examine the influence of fluoxymesterone (FM) on the inhibition of burst formation, we added 10(-10)-10(-7) M FM to the culture medium. Inhibition of burst formation by normal BFU-E was reduced from 73.4% to 58.2%-63.1%. These results suggest that FM stimulates proliferation and differentiation of normal BFU-E that are affected by inhibitory factors produced by leukemic cells.

Adult↗